School of Pharmacy, The University of Kansas, Lawrence, Kansas.
School of Pharmacy, The University of Kansas, Lawrence, Kansas.
J Am Acad Child Adolesc Psychiatry. 2021 Nov;60(11):1332-1334. doi: 10.1016/j.jaac.2021.08.018. Epub 2021 Sep 2.
Increasing coronavirus disease 2019 (COVID-19) vaccination rates has been identified by the US Centers of Disease Control and Prevention as critical to ending the COVID-19 pandemic. On May 10, 2021, the Pfizer-BioNTech COVID-19 vaccine (BNT162b2; Pfizer, Inc, New York, New York, and BioNTech SE, Mainz, Germany) was approved for emergency use authorization by the US Food and Drug Administration for patients 12 years of age or older. Here we report a retrospective study describing the implementation of a COVID-19 vaccination program at our child and adolescent psychiatric hospital. To our knowledge, this is the first report detailing the administration of the COVID-19 vaccination in this setting.
提高新型冠状病毒病 2019(COVID-19)疫苗接种率已被美国疾病控制与预防中心确定为结束 COVID-19 大流行的关键。2021 年 5 月 10 日,辉瑞-生物技术公司的 COVID-19 疫苗(BNT162b2;辉瑞公司,纽约州纽约市和生物技术公司 SE,美因茨,德国)获得美国食品和药物管理局的紧急使用授权,用于 12 岁及以上的患者。在这里,我们报告了一项回顾性研究,描述了我们儿童和青少年精神病院 COVID-19 疫苗接种计划的实施情况。据我们所知,这是第一份详细介绍在这种情况下 COVID-19 疫苗接种情况的报告。